Intercept
is a New Jersey-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of patients with non-viral liver diseases... Read moreIntercept
is a New Jersey-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of patients with non-viral liver diseases... Read more
News
Dec 12, 2024
Endpoints News
Intercept: 'Serious liver injury' cases on Ocaliva lead FDA to call for monitoring
Nov 14, 2024
Medthority
Intercept: Complete Response Letter for Ocaliva (obeticholic acid, OCA) for primary biliary cholangitis
Nov 13, 2024
Pharamceutical Technology
Intercept: Intercept loses Ocaliva FDA full approval bid in rare liver disease
Oct 18, 2024
PharmaLive
Intercept: FDA pushes back PDUFA dates for Amgen and Intercept
Oct 17, 2024
GlobalNewswire
Press Release: Intercept : Intercept Provides Regulatory Update Regarding sNDA for OCALIVA
Sep 13, 2024
Life Care News
Intercept: Company Statement on FDA Advisory Committee Meeting
Sep 11, 2024
Endpoints News
Intercept: FDA is poised to pull Ocaliva as adcomm documents question post-approval study results
Jun 29, 2024
The Pharma Letter
Intercept: BRIEF---EMA recommends revoking conditional authorization for Ocaliva
Jun 05, 2024
StreetInsider
Press Release: Intercept : Intercept Presents New Data on the Results of OCA-Bezafibrate Combination Therapy in PBC After Six Months of Treatment in Late-Breaking Poster Presentation at EASL Congress 2024
Feb 29, 2024
GlobalNewswire
Press Release: Intercept : Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva (obeticholic acid) for the Treatment of PBC
Intercept Competitors
1
2
3
4
5
6
7
8
9
10